Skip to content

Assessment of the Role of Incisura Biopsy in the Staging of Chronic Gastritis

Assessment of the Role of INCisura Biopsy in incrEASing the Stage of Chronic Gastritis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05744596
Acronym
INCREASE
Enrollment
400
Registered
2023-02-27
Start date
2023-03-23
Completion date
2027-03-01
Last updated
2026-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic; Gastritis, Atrophic

Brief summary

This prospective multicenter study investigates the added benefit of incisura biopsy to correct identification of patients with high-risk chronic gastritis (OLGA stages III-IV). It compares a biopsy protocol with and without a single incisura biopsy in a non-inferiority design. Anonymized photo and videodocumentation according to institution practices will constitute a databank for lesion recognition, quality improvement, and potential AI development.

Detailed description

The investigators will perform a prospective, multicenter, randomized controlled trial of 2 different gastric biopsy protocols. The hypothesis is that a gastric mapping protocol not including the incisura biopsy ("I-": 2 biopsies from the antrum, 2 from the corpus) is non-inferior to the conventional 5-biopsy approach ("I+": 2 biopsies from the antrum, 2 from the corpus, 1 from the incisura). The primary endpoint of this study is to assess the sensitivity of the "I-" protocol in diagnosing high-risk precancerous chronic gastritis (OLGA/OLGIM stages III or IV) compared to the assumed gold standard of histology based on the "I+" protocol. In designing the study, the investigators opted for a non-inferiority paired design with high-risk chronic gastritis as a primary binary outcome and a non-inferiority margin (Δ) of 5 % (two-sided 95% CI). The non-inferiority margin was established according to clinical judgement, taking into consideration the significance of a missed diagnosis of high-risk preneoplastic condition and previous estimates of the added value offered by the added incisura biopsy. With a power of 80% and a 2-sided α-level set at 0.05, it is estimated that 370 subjects are needed to show non-inferiority. Finally, 400 subjects will be enrolled to compensate for eventual exclusions or protocol deviations. Cohen's kappa will be used to rate intra and inter-observer concordance for pathologists. An intermediary analysis for futility is scheduled after 100 patients (25%) are enrolled.

Interventions

OTHERIncisura biopsy analysis

a pathologist blinded to the other biopsies analyzes the biopsy from the incisura

Sponsors

Clinical Hospital Colentina
Lead SponsorOTHER
Instituto Portugues de Oncologia, Francisco Gentil, Porto
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* indication to perform upper GI endoscopy for diagnosis or surveillance

Exclusion criteria

* lack of informed consent, previously diagnosed advanced gastric cancer, incomplete endoscopy, surgically altered stomach

Design outcomes

Primary

MeasureTime frameDescription
prevalence of OLGA III-IVat time of enrollmentnumber of patients with confirmed OLGA III-IV

Secondary

MeasureTime frameDescription
prevalence of OLGIM III-IVat time of enrollmentnumber of patients with confirmed OLGIM III-IV

Countries

Portugal, Romania

Contacts

CONTACTAndrei Voiosu
andreivoiosu@gmail.com+40213173245

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026